← Leaderboards
Janet L Brandsma
Yale University
$2,634,916
Attributed
$2,634,916
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $572.7K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,634,916 · 4
By mechanism
R01$1,601,588 · 1
R21$888,810 · 2
P30$144,518 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- John Rose$16,253,868
- Jorge E Galan$45,678,830
Others in their field
Top investigators on “Rabbit Papillomavirus”
- Christopher Fisher · Nanovir, Llc.$5,942,780
- Neil D Christensen · Pennsylvania State Univ Hershey Med Ctr$3,832,613
- Denise A. Galloway · Fred Hutchinson Cancer Center$3,660,874
- Lorenzo Giacani · University Of Washington$2,380,066
- Liang Qiao · Loyola University Chicago$2,150,332
- Warner King Huh · University Of Alabama At Birmingham$2,051,364
Research focus
Rabbit PapillomavirusDisease /Disorder ModelLaboratory RabbitHuman PapillomavirusPapillomaSexually Transmitted DiseasesTumorInvestigationMalignant - DescriptorLifeBaseMalignant NeoplasmsHuman Papilloma Virus InfectionRemission /RegressionChimeric ProteinsAntigen Antibody ReactionEnzyme Linked Immunosorbent AssayImmune ResponseImmunityInfectionMalignant Neoplasm Of Cervix UteriLesionCervix NeoplasmsTumor Antigens
Grant awards (11)
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis$223,425
R21 · FY2009 · CA · contact PI
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis$186,188
R21 · FY2008 · CA · contact PI
VSV-based Therapeutic Papilloma Vaccine$310,442
R01 · FY2007 · CA · contact PI
VSV-based Therapeutic Papilloma Vaccine$319,714
R01 · FY2006 · CA · contact PI
VSV-based Therapeutic Papilloma Vaccine$327,409
R01 · FY2005 · CA
Papillomavirus E2 as a cervical/anal cancer drug target$245,250
R21 · FY2005 · CA
VSV-based Therapeutic Papilloma Vaccine$327,409
R01 · FY2004 · CA
Papillomavirus E2 as a cervical/anal cancer drug target$233,947
R21 · FY2004 · CA
VSV-based Therapeutic Papilloma Vaccine$316,614
R01 · FY2003 · CA
CTL responses to vaccination in CRPV rabbit model$72,259
P30 · FY2001 · AR
CTL responses to vaccination in CRPV rabbit model$72,259
P30 · FY2000 · AR